Abstract
In looking for novel therapies for the effective treatment of ovarian cancer, particularly as an adjuvant to surgery, immunotherapy is an option which is ready to be explored. Two reasons why this option may now be a realistic one are that potential target antigens are being identified and considerable advances have been made in understanding the underlying mechanisms involved in tumour rejection and in antigen presentation and recognition by the various components of the immune system. The possibility of extending immunotherapy to prevention (at least for prevention of recurrence of the disease) is also a real one since active specific immunotherapy (ASI) appears to be unaccompanied by obvious serious side effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hung, M.C., Zhang, X., Yen, D.H. et al. (1992) Aberrant expression of the c-erbB-2/ neu protooncogene in ovarian cancer. Cancer Lγett., 61, 95–103.
Campbell, I.G., Jones, T.A., Foulkes, W.D. et al. (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res., 51, 5329–38.
Mazars, R., Pujol, P., Maudelonde, T. et al. (1991) p53 mutations in ovarian cancer: a late event? Oncogene, 6, 1685–90.
Lamb, P. and Crawford, L. (1986) Characterization of the human p53 gene. Cancer Res., 6, 1379–85.
Van der Bruggen, P., Traversari, C., Chomez, P. et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.Science, 254,1643–7.
Hird, V., Snook, D., Dhokia, B. et al. (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer, 68, 403–6.
Schwartz, R.H. (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065–8.
Linsley, P.S., Brady, W., Grosmaire, L. et al. (1992) Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, J.Exp. Med., 173, 721–30.
Chen, L., Ashe, S., Brady, W.A. et al. (1992) Costimulation of antitumour immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093–102.
Browning, M.J. and Bodmer, W.F. (1992) MHC antigens and cancer: implications for T-cell surveillance. Curr. Opinion Immunol 4,613–18.
Burchell, J. and Taylor-Papadimitriou, J. (1989) Antibodies to human milk fat globule molecules. Cancer Invest., 17, 53–61.
Gendler, S.J., Lancaster, C.A., Taylor-Papadimitriou, J. et al. (1990) Molecular cloning and expression of the human tumourassociated polymorphic epithelial mucin. J. Biol Chem., 265, 15286–93.
Ligtenberg, M., Vos, H., Gennissen, A. et al. (1990) Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J. Biol Chem., 265, 5573–8.
Wreschner, D.H., Hareuveni, M., Tsarfaty, I. et al. (1990) Human epithelial tumor antigen cDNA sequences. Eur. J. Biochem., 189,463–73.
Siddiqui, J., Abe, M., Hayes, D. et al. (1988) Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma- associated antigen. Proc. Natl Acad. Sci. USA, 85,2320–3.
Lan, M., Batra, S., Qi, W-N. et al. (1990) Cloning and sequencing of a human pancreatic tumour mucin cDNA. J. Biol. Chem., 265, 15294–9.
Burchell, J., Gendler, S.J., Taylor-Papadimitriou, J. et al. (1987) Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer. Res., 47, 5476–82.
Girling, J.R., Bartkova, J., Burchell, J. et al. (1989) A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer, 43, 1072–6.
Gunn, J.R., Byrd, J., Hicks, J. et al. (1989) Molecular cloning of human intestinal mucin cDNAs. J. Biol Chem., 264, 6480–7.
Gum, J.R., Hicks, J., Swallow, D. et al. (1990) Molecular cloning of cDNAs derived from a novel human intestinal mucin gene.Biochem. Biophys. Res. Commun., 171,407–15.
Porchet, N., van Cong, N., Dufosse, J. et al. (1991) Molecular cloning and chromosomal localization of a novel human tracheobronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. Biochem. Biophys. Res. Commun., 175,414–22.
Langdon, S.P., Lawrie, S.S., Hay, F.G. et al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res., 48, 6166–72.
Burchell, J., Taylor-Papadimitriou, J., Boshell, M. et al. (1989) A short sequence within the amino acid tandem repeat of a cancer associated mucin contains immunodominant epitopes. Int. J. Cancer, 44,691–6.
Taylor-Papadimitriou, J. (1991) Report on the First International Workshop on Carcinomaassociated Mucins. Int. J. Cancer, 49, 1–5.
Lancaster, C., Peat, N., Duhig, T. et al. (1990) Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem. Biophys. Res. Commun., 173, 1019–29.
Hanish, F.G., Uhlenbruck, G., Peter-Katalinic, J. et al. (1989) Structure of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyl-lactosamine backbones with Galiβ(l-4) GlcNAciβ(l-6) repeating units. J. Biol Chem., 265, 872–83.
Hull, S.R., Bright, A., Carraway, K.L. et al. (1989) Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line.Cancer Commun., 1, 261–7.
Van Daam, P.A., Lowe, D.G., Watson, J.V. et al. (1991) Multiparameter flow cytometric quantitation of the expression of the tumor- associated antigen SM3 in normal and neoplastic ovarian tissues. Cancer, 68,169–77.
Granowska, M, Mather, S.J., Jobling, T. et al. (1990) Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int. J. Biol. Markers, 5, 89–96.
Barnd, D.L., Lan, M.S., Metzgar, R.S. et al. (1989) Specific, major histocompatibilty complex-unrestricted recognition of tumor- associated mucins by human cytotoxic T cells.Proc. Natl. Acad. Sci. USA, 86, 7159–64.
Jerome, K.R., Barnd, K.L. Bendt, K.M. et al. (1991) Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognise an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.Cancer Res., 51, 2908–16.
Rughetti, A., Turchi, V., Apolonj Ghetti, C. et al. (1993) Human B cell immune response against the polymorphic epithelial mucin (PEM). Cancer Res., 53, 2457–90.
Fung, P.Y.S., Made], M., Koganty, R. et al. (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res., 50, 4308.
Singhal, A., Fohn, M. and Hakomori, S. (1991)Induction of α-N-acetylgalactosamine- O-serine/threonine (Tn) antigen-mediated. cellular immune response for active immunotherapy in mice. Cancer Res., 51, 1406–14.
MacLean, G.D., Bowen-Yacyshyn, M.B., Samuel, J. et al. (1992) Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen- 43. Friedenreich) determinant using a synthetic carbohydrate antigen, J.Immunother., 11, 292–305.
Lalani, E.N., Berdichevsky, F., Boshell, M. et al. (1991) Expression of the gene coding for a human mucin in mouse mammary tumour cells can affect their tumorigenicity. J. Biol Chem., 266, 15420–6.
Ding, L., Lalani, E.N., Reddish, M. et al. (1993) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUCl mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUCl gene. J. Cancer Immunol Immunother., 36, 9–17.
Vos, H.L., Devarayalu, Y., de Vries, Y. and Bornstein, P. (1992) Thrombospondin 3 (Thbs3), a new member of the thrombospondin gene family. J. Biol Chem., 267, 12192–6.
Peat, N., Gendler, S.J., Lalani, E.N., (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUCl) in transgenic mice. Cancer Res., 52, 1954–60.
Kovarik, A., Peat, N., Wilson, D. et al. (1993) Analysis of the tissue specific promoter of the MUCl gene. J.Biol Chem., 268,9917–26.
Aldovini, A. and Young, R.A. (1991) Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature, 35, 1479–82.
Dranoff, G., Jaffee, E., Lazenby, A. et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte- macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA, 90, 3539–43.
Tao, M.H. and Levy, R. (1993) A novel vaccine for B-cell lymphoma: idiotype/granulocyte- macrophage colony-stimulating factor fusion protein. Nature, 362, 755–8.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Chapman & Hall
About this chapter
Cite this chapter
Taylor-Papadimitriou, J., Peat, N., Burchell, J., Beverley, P., Smith, M. (1995). Potential for immunotherapy: PEM as a target antigen. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_30
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0136-4_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0138-8
Online ISBN: 978-1-4757-0136-4
eBook Packages: Springer Book Archive